Prevalence and risk factors of human papillomavirus infection types 16/18/45 in a cohort of French females aged 15-23years

被引：11

作者：

Baudu A. ^{[1
,2
]}

Prétet J.-L. ^{[1
,2
,3
]}

Riethmuller D. ^{[1
,2
,3
]}

Chotard M. ^{[2
,3
]}

Mougin C. ^{[1
,2
,3
]}

Mercier M. ^{[1
,2
,3
]}

机构：

[1] Univ Franche-Comte

[2] EA 3181, FED4234

[3] CHU Besancon

来源：

Journal of Epidemiology and Global Health | 2014年 / 4卷 / 1期

关键词：

Epidemiology; Genotyping; HPV infection; Screening; Young females;

D O I：

10.1016/j.jegh.2013.11.003

中图分类号：

学科分类号：

摘要：

Investigation of the prevalence and risk factors of human papillomavirus (HPV) infection is the basis for developing prophylactic strategies against cervical cancer, especially for young women. This study aimed to assess the prevalence and risk factors of HPV infection among a cohort of sexually active young French women eligible for catch-up vaccination. Between 1997 and 2007, 2163 women aged 15-23. years attending consultations at the department of gynecology in the Hospital of Besançon (France) were screened for high risk HPV (HR HPV) infection. Risk factors were investigated through a questionnaire sent to all participants in 2010. HPV DNA was detected by HC2 and Probe Set assays. The overall prevalence for HR HPV and HPV16, 18 and/or HPV45 was 44.6% (95% CI, 42.5-46.7%) and 19% (95% CI, 17.3-20.7%), respectively. The response rate to the questionnaire was 22.6%. The prevalence of independent risk factors (age older than 19, smoking, and oral contraception) for HPV 16/18/45 infection in this population was less than 20%. Based on this study, HPV vaccination should be offered not only to teenage girls, but also to young women, regardless of their sexual activity. © 2014 Ministry of Health, Saudi Arabia.

引用

页码：35 / 43

页数：8

共 47 条

[1]

Bosch F.X., de Sanjose S., Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality, J Natl Cancer Inst Monogr, 31, pp. 3-13, (2003)

[2]

Moscicki A.B., Impact of HPV infection in adolescent populations, J Adolesc Health, 37, (2005)

[3]

Koutsky L., Epidemiology of genital human papillomavirus infection, Am J Med, 102, pp. 3-8, (1997)

[4]

Woodman C.B., Collins S., Winter H., Bailey A., Ellis J., Prior P., Et al., Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study, Lancet, 357, pp. 1831-1836, (2001)

[5]

Moscicki A.B., Shiboski S., Broering J., Powell K., Clayton L., Jay N., Et al., The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women, J Pediatr, 132, pp. 277-284, (1998)

[6]

Franco E.L., Villa L.L., Sobrinho J.P., Prado J.M., Rousseau M.C., Desy M., Et al., Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer, J Infect Dis, 180, pp. 1415-1423, (1999)

[7]

Castellsague X., Bosch F.X., Munoz N., Environmental co-factors in HPV carcinogenesis, Virus Res, 89, pp. 191-199, (2002)

[8]

Cogliano V., Grosse Y., Baan R., Straif K., Secretan B., El Ghissassi F., Et al., Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment, Lancet Oncol, 6, pp. 552-553, (2005)

[9]

Moreno V., Bosch F.X., Munoz N., Meijer C.J., Shah K.V., Walboomers J.M., Et al., Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study, Lancet, 359, pp. 1085-1092, (2002)

[10]

Munoz N., Franceschi S., Bosetti C., Moreno V., Herrero R., Smith J.S., Et al., Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study, Lancet, 359, pp. 1093-1101, (2002)

← 1 2 3 4 5 →